Callan Family Office LLC Buys New Shares in Repligen Co. (NASDAQ:RGEN)

Callan Family Office LLC bought a new position in Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,016 shares of the biotechnology company's stock, valued at approximately $434,000.

Other large investors have also made changes to their positions in the company. QRG Capital Management Inc. boosted its position in shares of Repligen by 12.5% in the third quarter. QRG Capital Management Inc. now owns 3,642 shares of the biotechnology company's stock worth $542,000 after buying an additional 406 shares during the period. Equitable Trust Co. grew its stake in Repligen by 52.8% during the 3rd quarter. Equitable Trust Co. now owns 2,577 shares of the biotechnology company's stock valued at $384,000 after acquiring an additional 891 shares in the last quarter. Verdence Capital Advisors LLC increased its holdings in shares of Repligen by 20.6% in the 3rd quarter. Verdence Capital Advisors LLC now owns 3,808 shares of the biotechnology company's stock valued at $567,000 after purchasing an additional 651 shares during the period. Atria Investments Inc lifted its position in shares of Repligen by 67.9% in the third quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company's stock worth $477,000 after purchasing an additional 1,295 shares in the last quarter. Finally, TimesSquare Capital Management LLC boosted its holdings in shares of Repligen by 14.6% during the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company's stock worth $41,019,000 after purchasing an additional 35,115 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a report on Friday, February 21st. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $181.00.

Repligen Stock Performance

Shares of Repligen stock traded down $2.93 on Thursday, reaching $142.44. The stock had a trading volume of 462,196 shares, compared to its average volume of 643,248. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $200.23. The business's 50-day moving average price is $157.18 and its two-hundred day moving average price is $148.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market cap of $7.98 billion, a P/E ratio of -279.29, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, sell-side analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.